Metabolic reprogramming is a hallmark of cancer, and it supports the increased energetic, biosynthetic, and redox demands associated with tumor development and progression.

Therapeutic approaches exploiting differential metabolic requirements of tumor cells are under investigation and in clinical trials. At the same time, mitochondrial toxicity has been implicated in clinical trial attrition and black box warnings, making predictive screening an important step in the drug development process.

Standard approaches to monitoring compound-induced metabolic perturbations rely on endpoint assays that provide limited kinetic information and lack cell-specific data in co-culture models. Live-cell analysis holds promise for greater physiological relevance and insight by providing the necessary tools to study dynamic cells changes in translational models.

Watch this webinar, presented by Cicely Schramm.

#livecellanalysis #cellanalysis #cancerresearch #oncology #metabolicreprogramming